Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin

NCT02429258 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02429258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02429258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2015
Completion date
October 31, 2015
Enrollment
226 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

type ii diabetes